Clinical Evidence
Our treatment protocols are built on peer-reviewed clinical trial data from the world's leading medical journals.
GLP-1 Evidence (Semaglutide)
- STEP 1 Trial: 14.9% average body weight reduction over 68 weeks (NEJM 2021)
- STEP 2 Trial: 9.6% reduction in patients with type 2 diabetes (Lancet 2021)
- SELECT Trial: 20% reduction in major cardiovascular events (AHA 2023)
Dual Agonist Evidence (Tirzepatide)
- SURPASS 1-5 Trials: 18-22% average weight reduction (NEJM 2022)
- SURMOUNT-1: 22.5% weight loss at highest dose (NEJM 2022)
Triple Agonist Evidence (Retatrutide)
- Phase 2 Trial: 24.2% weight loss at 48 weeks — highest ever recorded (NEJM 2023)
- Phase 3 Trials: Currently enrolling, results expected 2025-2026
All data sourced from peer-reviewed publications. Explore GLP-3 research →